Umoja Biopharma Wins FDA IND Clearance for First CD22-Directed In Vivo CAR T Cell Therapy

Clinical-stage biotechnology company, Umoja Biopharma, has received FDA clearance of its IND application for UB-VV400, a CD22-directed in vivo CAR T-cell therapy candidate built on the company’s VivoVec lentiviral platform, positioning it as the industry’s first known in vivo CAR T program targeting CD22 for relapsed or refractory B-cell malignancies.